Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.

Artaç, Mehmet; Çoşkun, HASAN; Korkmaz, Levent; Koçer, Murat; Turhal, Nazım; Engin, Hüseyin; Dede, İsa; Paydaş, Semra; Öksüzoğlu, Berna; Bozcuk, Hakan; Demirkazık, Ahmet

doi:10.1016/j.clgc.2016.04.021

Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.

Atıf İçin Kopyala

Artaç M., Çoşkun H. Ş., Korkmaz L., Koçer M., Turhal N. S., Engin H., ...Daha Fazla

Clinical genitourinary cancer, cilt.14, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.clgc.2016.04.021
Dergi Adı: Clinical genitourinary cancer
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Cytokine therapy, VEGF inhibitors, Progression free survival, Sorafenib, Sunitinib, ENDOTHELIAL GROWTH-FACTOR, SUNITINIB, INTERLEUKIN-2, THERAPY, SU11248
Akdeniz Üniversitesi Adresli: Evet

Özet

Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.